Cardiovascular aspects of antipsychotics

Area of Science:

• Cardiology
• Psychiatry
• Pharmacology

Background:

• Schizophrenia is linked to increased mortality and reduced life expectancy, with cardiovascular disease as the primary cause of death.
• Antipsychotic medications, while crucial for managing schizophrenia, can negatively impact cardiovascular disease risk factors.

Purpose of the Study:

• To review the complex relationship between antipsychotic treatment and cardiovascular disease in patients with schizophrenia.
• To highlight the increased cardiovascular mortality and morbidity in schizophrenia patients.

Main Methods:

• This is a review article, synthesizing existing research on schizophrenia, antipsychotics, and cardiovascular disease.
• The review focuses on the impact of antipsychotics on metabolic syndrome and cardiovascular risk factors.

Main Results:

• Schizophrenia patients experience higher overall and cardiovascular mortality.
• These patients are at increased risk for metabolic syndrome, including weight gain, dyslipidemia, and diabetes, particularly with certain antipsychotics like clozapine and olanzapine.
• Differences in antipsychotic effects on metabolic parameters exist, but their long-term impact on mortality remains unclear.

Conclusions:

• Further research is essential to elucidate the intricate links between schizophrenia, antipsychotic therapy, and cardiovascular outcomes.
• Developing more effective strategies to mitigate cardiovascular disease burden in schizophrenia patients is critical.